Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.

Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, Hamilton RH, Sherwin P, McLain R, Arnold SE.

Arch Neurol. 2011 Nov;68(11):1398-403. doi: 10.1001/archneurol.2011.153.

2.

An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients.

Wong DF, Moghekar AR, Rigamonti D, Brašić JR, Rousset O, Willis W, Buckley C, Smith A, Gok B, Sherwin P, Grachev ID.

Mol Imaging Biol. 2013 Apr;15(2):230-7. doi: 10.1007/s11307-012-0583-x.

3.

[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.

Rinne JO, Wong DF, Wolk DA, Leinonen V, Arnold SE, Buckley C, Smith A, McLain R, Sherwin PF, Farrar G, Kailajärvi M, Grachev ID.

Acta Neuropathol. 2012 Dec;124(6):833-45. doi: 10.1007/s00401-012-1051-z.

PMID:
23053137
4.

Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients.

Leinonen V, Rinne JO, Virtanen KA, Eskola O, Rummukainen J, Huttunen J, von Und Zu Fraunberg M, Nerg O, Koivisto AM, Rinne J, Jääskeläinen JE, Buckley C, Smith A, Jones PA, Sherwin P, Farrar G, McLain R, Kailajärvi M, Heurling K, Grachev ID.

Eur J Neurol. 2013 Jul;20(7):1043-52. doi: 10.1111/ene.12102.

PMID:
23398333
5.

Prospective flutemetamol positron emission tomography and histopathology in normal pressure hydrocephalus.

Rinne JO, Frantzen J, Leinonen V, Lonnrot K, Laakso A, Virtanen KA, Solin O, Kotkansalo A, Koivisto A, Sajanti J, Karppinen A, Lehto H, Rummukainen J, Buckley C, Smith A, Jones PA, Sherwin P, Farrar G, McLain R, Kailajarvi M, Grachev ID.

Neurodegener Dis. 2014;13(4):237-45. doi: 10.1159/000355256.

PMID:
24296542
6.

Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus.

Leinonen V, Rinne JO, Wong DF, Wolk DA, Trojanowski JQ, Sherwin PF, Smith A, Heurling K, Su M, Grachev ID.

Acta Neuropathol Commun. 2014 Apr 22;2:46. doi: 10.1186/2051-5960-2-46.

7.

Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway S.

JAMA Neurol. 2015 Mar;72(3):287-94. doi: 10.1001/jamaneurol.2014.4144.

PMID:
25622185
8.

Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.

Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, Sherwin P.

J Nucl Med. 2014 Oct;55(10):1623-8. doi: 10.2967/jnumed.114.142109.

9.

An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.

Senda M, Yamamoto Y, Sasaki M, Yamane T, Brooks DJ, Farrar G, McParland B, Heurling K.

Ann Nucl Med. 2015 Jun;29(5):391-9. doi: 10.1007/s12149-015-0957-7.

PMID:
25874747
10.

Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B.

Adamczuk K, Schaeverbeke J, Nelissen N, Neyens V, Vandenbulcke M, Goffin K, Lilja J, Hilven K, Dupont P, Van Laere K, Vandenberghe R.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):142-51. doi: 10.1007/s00259-015-3156-9.

PMID:
26260650
11.

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.

JAMA Neurol. 2014 Oct;71(10):1282-9. doi: 10.1001/jamaneurol.2014.1358.

PMID:
25155658
12.

Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.

Vandenberghe R, Nelissen N, Salmon E, Ivanoiu A, Hasselbalch S, Andersen A, Korner A, Minthon L, Brooks DJ, Van Laere K, Dupont P.

Neuroimage. 2013 Jan 1;64:517-25. doi: 10.1016/j.neuroimage.2012.09.015.

PMID:
22982358
13.

Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.

Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Någren K, Tapiola T, Pirttilä T, Rinne J, Jääskeläinen JE, Soininen H, Rinne JO.

Arch Neurol. 2008 Oct;65(10):1304-9. doi: 10.1001/archneur.65.10.noc80013.

PMID:
18695050
14.

Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.

Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM.

Arch Neurol. 2011 Nov;68(11):1404-11. doi: 10.1001/archneurol.2011.150.

PMID:
21747008
15.

Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.

de Lartigue J.

Drugs Today (Barc). 2014 Mar;50(3):219-29. doi: 10.1358/dot.2014.50.3.2116672.

PMID:
24696867
16.

Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data.

Lundqvist R, Lilja J, Thomas BA, Lötjönen J, Villemagne VL, Rowe CC, Thurfjell L.

J Nucl Med. 2013 Aug;54(8):1472-8. doi: 10.2967/jnumed.112.115006.

17.

[(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.

Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, Smith AP, Buckley C.

Alzheimers Dement. 2015 Aug;11(8):975-85. doi: 10.1016/j.jalz.2015.05.018.

18.

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ.

Ann Neurol. 2010 Sep;68(3):319-29. doi: 10.1002/ana.22068.

PMID:
20687209
19.

Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.

Vallabhajosula S.

Semin Nucl Med. 2011 Jul;41(4):283-99. doi: 10.1053/j.semnuclmed.2011.02.005. Review.

PMID:
21624562
20.

Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.

Heurling K, Leuzy A, Zimmer ER, Lubberink M, Nordberg A.

Eur J Nucl Med Mol Imaging. 2016 Feb;43(2):362-73. doi: 10.1007/s00259-015-3208-1. Review.

PMID:
26440450
Items per page

Supplemental Content

Support Center